Author:
Ruperto Nicolino,Martini Alberto
Publisher
Springer Science and Business Media LLC
Reference10 articles.
1. Martini, A. & Lovell, D. J. Juvenile idiopathic arthritis: state of the art and future perspectives. Ann. Rheum. Dis. 69, 1260–1263 (2010).
2. FDA. Early communication about an ongoing safety review of tumor necrosis factor (TNF) blockers (marketed as remicade, enbrel, humira, and cimzia).
http://www.fda.gov/
[online]
, (2008).
3. Diak, P. et al. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum. 62, 2517–2524 (2010).
4. Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann. Rheum. Dis. 69, 964–975 (2010).
5. Cabral, D. A. & Tucker, L. B. Malignancies in children who initially present with rheumatic complaints. J. Pediatr. 134, 53–57 (1999).
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献